- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05029739
An E-health Intervention for Patients With Peripheral Artery Disease (I-PAD)
An Interactive E-health Intervention to Promote Walking Capacity and Life-style Changes in Peripheral Artery Disease (iPAD)
Study Overview
Status
Conditions
Detailed Description
Peripheral artery disease (PAD) is a highly prevalent atherosclerotic syndrome with an estimated global population burden of ~200 million people. PAD patients are at heightened risk for adverse cardiovascular- and limb events and impaired quality of life. Cigarette smoking is the most important modifiable risk factor. Patients with PAD who smoke have higher disease progression rates, greater risk of complications, poor post-procedural outcomes, compromised functional status, and increased hospitalizations.
A significant goal of PAD treatment includes risk factor modification and prevention of cardiovascular events. Guideline-directed therapy includes cardioprotective pharmacotherapies, and lifestyle modification. Nevertheless, adherence to pharmacologic and lifestyle recommendations in PAD is uncertain. Effective non-pharmacologic therapies for PAD also exist, including smoking cessation, exercise support, and diet counseling. However, limited data is available on mobile applications offering digitally delivered lifestyle change support, including a structured exercise program and smoking cessation support. This study aims to digitally provide lifestyle change support, including a structured and PAD-focused lifestyle program and smoking cessation support via a mobile platform (Sidekick Health) with the primary aim to increase patients' walking ability and secondary aims to reduce smoking and improve medication adherence.
Hypotheses
- At the end of the 12 weeks, the interventional arm will reach a clinically meaningful change in walking ability, as compared to controls, measured by a change in the 6-MWT at twelve-week, and 12 months; the minimal clinically important difference (MCID) is defined as +12m.
- At the end of the 12 weeks, ≥15% interventional treatment arm participants will give up smoking or have significantly reduced their daily smoking compared to less than <10% in the control arm.
- At the end of the 12 weeks, ≥50% of interventional treatment arm participants will improve their medication adherence from pre- until post-intervention as compared to <30% in the control arm.
- Healthcare cost will be reduced at 12 month follow-up in the intervention arm.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gothenburg, Sweden
- Sahlgrenska University Hospital
-
Jönköping, Sweden
- Jönköping Central Hospital
-
Karlstad, Sweden
- Karlstad Central Hospital
-
Malmö, Sweden
- Skåne University Hospital
-
Stockholm, Sweden
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults with confirmed PAD referred to a vascular surgery unit for evaluation and treatment, currently on best medical treatment and own/have access to a mobile smartphone
- Stable PAD disease and limb symptoms during the last 3 months.
- PAD is the activity-limiting disease
- Abnormal resting ankle-brachial index (ABI) (≤0.90), falsely elevated ABI above 1.3 or a 30% post-exercise ABI reduction.
Exclusion Criteria:
- Critical limb ischemia, prior amputation, or other diseases/ impairment that limit the walking ability and the 6-minute walk test's proper conduct
- Cognitive impairment
- Prior revascularization less than one year ago
- A planned revascularization procedure during the upcoming 12 months (known at baseline).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E-intervention group
Participants will be instructed to download a life-style-changing mobile app to which they will have access for 12 weeks.
After the first week of the program, participants who smoke will be offered to incorporate smoking cessation support into their PAD program.
These changes are minor and not intended to divide the intervention group in two but instead to personalize the study experience.
The program aims to empower positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
|
See description of the e-intervention group as above.
|
Active Comparator: Standard of care - control group.
All patients in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, smoking cessation advise and advise on modifiable risk factors.
The control arm will also receive an information leaflet about relevant lifestyle modifications for PAD.
After the baseline measurements and data collection, there will be no scheduled visits to a health care provider until week 12.
|
See description of the e-intervention group as above.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six-minute walk test.
Time Frame: 12 weeks and 12 months
|
Change in objectively measured (pain-free and maximal) walking capacity (as measured with the 6-Minute Walk Distance Test) from baseline to 12 weeks and 12 months
|
12 weeks and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Smoking status
Time Frame: 12 weeks and 12 months
|
Change in patients´ daily smoking patterns from pre to post-intervention and at 12-months.
This outcome will be measured through a carbon mononoxide exhalor test and by patient-reported daily frequency of cigarettes smoked at baseline, 12 weeks and 12 months
|
12 weeks and 12 months
|
Increased readiness to quit smoking.
Time Frame: 12 weeks and 12 months
|
This outcome will be measured through the smoking 'Readiness to quit' questionnaire (The Contemplation Ladder) at baseline, 12 weeks and 12 months.
|
12 weeks and 12 months
|
Medication adherence improvement
Time Frame: 12 weeks and 12 months
|
To determine patients' adherence to their medications after the usage of the smartphone application as compared to standard of care.
This secondary outcome will be measured through a questionnaire; Morisky Medication Adherence Scale, MMAS-8 at baseline, 12 weeks and 12 months.
|
12 weeks and 12 months
|
Disease-specific health-related quality of life.
Time Frame: 12 weeks and 12 months
|
Health related quality of life; measured by the disease-specific questionnaire VascuQoL-6 at baseline, 12 weeks and 12 months.
|
12 weeks and 12 months
|
Comparing outcomes to health literacy
Time Frame: 12 weeks and 12 months
|
Comparing outcomes to health literacy measured through a questionnaire; HLS-EU-Q16 at baseline.
|
12 weeks and 12 months
|
Quality Adjusted Life Years (QALYs)
Time Frame: 12 months
|
Calculated based on recorded accumulated costs and registered EQ5D-5L outcomes
|
12 months
|
Change in self-assessed stress levels
Time Frame: 12 weeks
|
Self-reported ordinal scale ranging from 0 to 10
|
12 weeks
|
Change in self-assessed sleep quality levels
Time Frame: 12 weeks
|
Self-reported ordinal scale ranging from 0 to 10
|
12 weeks
|
Change in self-assessed energy levels
Time Frame: 12 weeks
|
Self-reported ordinal scale ranging from 0 to 10
|
12 weeks
|
Change in free living physical activity
Time Frame: 12 Weeks
|
Measured as total step count per day
|
12 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Joakim Nordanstig, MD,PhD, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Sweden.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I-PAD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intermittent Claudication
-
Mid and South Essex NHS Foundation TrustRecruitingPeripheral Arterial Disease | Claudication, IntermittentUnited Kingdom
-
Louis MessinaBioMarin PharmaceuticalRecruitingPeripheral Vascular Diseases | Peripheral Artery Disease | Claudication, IntermittentUnited States
-
University Hospital, AngersCompletedPeripheral Artery Disease | Claudication, IntermittentFrance
-
Palo Alto Veterans Institute for ResearchSociety for Vascular SurgeryWithdrawnPeripheral Artery Disease | Claudication, Intermittent
-
Biotronik AGCompletedSevere Intermittent Claudication | Patients With Symptomatic Critical Limb IschemiaGermany
-
University Hospital, EssenStraub Medical AGUnknownPeripheral Arterial Disease | Claudication, IntermittentGermany
-
University Hospital, EssenUnknownPeripheral Arterial Disease | Claudication, IntermittentGermany
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity Hospital, Angers; Imperial College London; Sheffield Hallam UniversityCompletedIntermittent ClaudicationUnited Kingdom
-
Paradigm SpineCompletedIntermittent Neurogenic Claudication (INC) as a Result of Spinal StenosisNetherlands
-
Imperial College LondonTerminatedStandardised Claudication Treadmill TestUnited Kingdom